Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities

Core Points - Waldencast plc has sold its rights to the "Obagi" trademark in Japan to Rohto Pharmaceutical Co., Ltd. for USD $82.5 million [1] - The transaction is part of Waldencast's strategy to improve its capital structure and maximize shareholder value [5][6] Financial Transactions - Rohto has been licensing the "Obagi" mark since 2002, and royalties from this arrangement accounted for 3% of net revenue for the Obagi Medical business for the fiscal year ended December 31, 2024 [2] - Waldencast has entered into a new credit agreement with Lumina Capital Management for a secured first-lien term loan facility of $225 million, aimed at improving liquidity and supporting brand growth [3][4] - Proceeds from the sale to Rohto will be used to repay a significant portion of the new loan facility, further deleveraging the company's balance sheet [4] Strategic Focus - The company is currently reviewing a range of strategic alternatives to enhance shareholder value, with the recent transactions reflecting this ongoing focus [5] - The CEO of Waldencast expressed that these transactions will substantially strengthen the company's balance sheet while exploring strategic options [6]